Background: Posterior fossa syndrome (PFS) is a rare manifestation of ponto-mesencephalic lesions frequently reported in post-surgical pediatric tumors, rarely described as a consequence of vascular, infective or inflammatory lesions. Objective: The aim of this article is to report the clinical and neuroradiological characteristics of a patient with an acute PFS presentation as a relapse in relapsing–remitting MS, significantly responsive to Alemtuzumab treatment. Case report: 24-year-old patient affected by multiple sclerosis developed motor-cognitive and behavioral syndrome related to an extensive ponto-mesencephalic lesion under Fingolimod treatment. Conclusion: Our case highlights the significant and rapid effect of Alemtuzumab therapy on both cognitive and motor symptoms occurring during a MS relapse with atypical neuroradiological localization
Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis / Signoriello, E.; D'Amico, A.; Fratta, M.; Ugga, L.; Altobelli, C.; Conchiglia, G.; Barbarulo, A. M.; Di Pietro, A.; Anastasio, P.; Rossi, F.; Lus, G.. - In: MULTIPLE SCLEROSIS AND RELATED DISORDERS. - ISSN 2211-0348. - 38:(2020), p. 101518. [10.1016/j.msard.2019.101518]
Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis
Signoriello E.
;Ugga L.;Di Pietro A.;
2020
Abstract
Background: Posterior fossa syndrome (PFS) is a rare manifestation of ponto-mesencephalic lesions frequently reported in post-surgical pediatric tumors, rarely described as a consequence of vascular, infective or inflammatory lesions. Objective: The aim of this article is to report the clinical and neuroradiological characteristics of a patient with an acute PFS presentation as a relapse in relapsing–remitting MS, significantly responsive to Alemtuzumab treatment. Case report: 24-year-old patient affected by multiple sclerosis developed motor-cognitive and behavioral syndrome related to an extensive ponto-mesencephalic lesion under Fingolimod treatment. Conclusion: Our case highlights the significant and rapid effect of Alemtuzumab therapy on both cognitive and motor symptoms occurring during a MS relapse with atypical neuroradiological localizationI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
